Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement According to 2022 KSH(Korean Society of Hypertension) Guidelines (SHIFT)

NCT06130124 is registered in ClinicalTrials.gov with Hanlim Pharm. Co., Ltd. as lead sponsor.

NCT NCT06130124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06130124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement According to 2022 KSH(Korean Society of Hypertension) Guidelines (SHIFT)
Lead sponsor
Hanlim Pharm. Co., Ltd.
Phase
Observational
Overall status
Unknown status
Start date
February 22, 2023
Completion date
July 25, 2025
Enrollment
5,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension